Exact presentation first
“Wegovy pen” can now mean more than one injection device
The Novo Nordisk Wegovy structured product label effective June 18, 2026 includes single-dose pens, single-dose prefilled syringes, a FlexTouch single-patient-use pen, and once-daily tablets. A yellow-bar question belongs to the current single-dose pen instructions; FlexTouch, prefilled-syringe, and tablet directions use different checkpoints. Device advice is unsafe when the presentation has not been identified.
- Read the carton and pharmacy label and match the device to the supplied Instructions for Use before interpreting a click, window, counter, needle, or plunger.
- Do not apply a single-dose pen’s yellow-bar rule to FlexTouch or a prefilled syringe, and do not use click-count charts to estimate a dose.
- Wegovy tablets have no pen or injection checkpoint; verify the route before treating a missed tablet as a device problem.
Single-dose pen checkpoint
A stopped yellow bar or medicine on the skin can mean an uncertain dose
For the current Wegovy single-dose pen, injection starts when the needle cover is pressed firmly against the skin. The instructions say to keep applying pressure until the yellow bar has stopped moving. They warn that medicine may appear on the skin or squirt from the needle and the full dose may not be received if the pen is removed too early or pressure is not maintained for the entire injection. They also direct the patient to contact the healthcare provider or Novo Nordisk if the yellow bar does not start moving or stops during the injection.
- Do not infer a delivered percentage from the amount of liquid seen, the number of clicks, the time against the skin, or a photo of the window.
- If the pen has already been removed, the needle cover locks; the instructions say the injection cannot be stopped and restarted later.
- Keep the device and packaging available for the prescriber, pharmacist, manufacturer, or adverse-event report, but handle the exposed needle as a sharps risk.
Dose uncertainty
Do not “make up” an uncertain injection on your own
A device problem is not automatically a confirmed missed dose. Some medicine may have entered, none may have entered, or the full amount may have been delivered despite a confusing sound or appearance. Giving another injection without product-specific advice can create an unintended extra dose, while assuming delivery can also leave the treatment plan uncertain. The responsible clinician or pharmacist needs the exact presentation, prescribed schedule, event details, symptoms, and other medicines before advising what happens next.
- Do not repeat, split, retime, double, or combine injections and do not borrow another person’s pen.
- Do not switch to Wegovy tablets, Ozempic, compounded semaglutide, or another GLP-1 product to repair the schedule.
- If the next scheduled dose is approaching before an answer arrives, contact the prescribing team or dispensing pharmacist again rather than applying a generic missed-dose rule to an uncertain injection.
Product and storage review
Preserve the details needed to evaluate a possible malfunction
A useful device report separates a product defect from storage damage, package damage, a presentation mix-up, unclear training, or an uncertain injection. Preserve the carton and patient label and record the product name, presentation, strength, lot, expiration date, pharmacy, shipment and storage history, solution appearance, cap or needle condition, window or counter behavior, clicks, visible leakage, and when the device was removed. Do not dismantle a pen or transfer its contents to investigate it.
- Do not use a device that is damaged, previously used, expired, frozen, improperly stored, cloudy or discolored when the instructions require a clear colorless solution, or associated with visible particles.
- Use Novo Nordisk support for a branded Wegovy presentation and the dispensing pharmacy for prescription and replacement questions; coverage or replacement is not guaranteed.
- FDA MedWatch accepts reports about serious adverse events and product-quality problems; emergency symptoms still require medical care rather than only a report.
Compounded-product boundary
Wegovy device instructions do not apply to compounded semaglutide
Wegovy is an FDA-approved finished branded drug. A patient-specific compounded semaglutide prescription may use a vial, syringe, different concentration, inactive ingredients, supplies, storage instructions, and beyond-use date. It is not FDA-approved Wegovy or an FDA-approved generic finished product and does not inherit the Wegovy pen’s clicks, yellow bar, device support, or replacement pathway.
- For a compounded prescription, contact the dispensing pharmacy and prescriber with the patient label, concentration, container, supplies, refill, storage, and exact event.
- Do not use a Wegovy troubleshooting video to estimate syringe units, transfer medicine, reconstitute powder, or improvise a replacement dose.
- Avoid research-use products, counterfeit pens, unlabeled syringes, loose powder, copied dose charts, and sellers that bypass prescription-first clinician review.
Safety escalation
Separate a device question from an urgent medical problem
Most uncertain injections need prompt product-specific advice, but symptoms determine whether waiting for a portal response is appropriate. Trouble breathing, throat tightness, facial or tongue swelling, fainting, severe confusion, or widespread rapidly worsening hives can require emergency care. Severe or persistent vomiting, inability to keep fluids down, severe abdominal pain, signs of dehydration, or concerning low-blood-sugar symptoms—especially with insulin or a sulfonylurea—need timely clinical assessment. A needle-stick injury or medicine exposure to the eye also needs immediate first-aid and professional guidance.
- Use emergency services for breathing or throat symptoms, facial or tongue swelling, fainting, severe confusion, or a rapidly worsening whole-body reaction.
- Seek timely assessment for severe abdominal pain, repeated vomiting, inability to hydrate, severe weakness, markedly reduced urination, or concerning glucose symptoms.
- Do not delay urgent care while trying to obtain a replacement device, calculate the dose, or complete a MedWatch report.